Floatz logo

Bms-907351

Renal Carcinoma Metastatic

Spanish Oncology Genito-Urinary GroupPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Renal Carcinoma Metastatic cohort.

Asset / SponsorPhaseRating
Axitinib
Consorzio Oncotech
Phase 2CCC
Avelumab
Consorzio Oncotech
Phase 2CCC
Darleukin
Philogen S.p.A.
Phase 1CC
Ruxolitinib
Philogen S.p.A.
Phase 1CC

Same molecule, other indications

Bms-907351 is also rated in:

renal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →